Case report: regression of MGUS with long-term use of curcumin!
I wonder if these case reports will ever catch the eye of our MM organisations, which, unfortunately, are so heavily sponsored by big Pharma…Doubtful…   Well, Margaret, this is intended to be a celebratory post, and I really don’t have the energy to dive into THAT discussion again. It’s just so bloody frustrating that sometimes I have to let off some steam. But no, not today. Today is a super good day! Pinga, 14.5 years old A new case report, led by Terry Golombick (if you don’t know who she is, you can do a search of my blog…she’s one of my favourite people on the planet…!!...
Source: Margaret's Corner - March 27, 2024 Category: Cancer & Oncology Authors: Margaret Tags: Blogroll case report on curcumin MGUS patient and curcumin Terry Golombick Source Type: blogs

Redi Health Lands $14 Million Investment to Continue Improving Patient Health Outcomes by Connecting Pharma, Providers, and Patients in One Platform
Series B Funding Round Led by Blue Heron Capital, with Participation from North Coast Ventures, Refinery Ventures, Mutual Capital Partners, Rev1 Ventures, and M25 Redi Health today announced that it has closed $14 million in Series B funding. The funding round was led by Blue Heron Capital, with participation from North Coast Ventures and existing investors Refinery Ventures, Mutual Capital Partners, Rev1 Ventures, and M25. Redi Health will use the financing to foster innovation, develop and launch new products, expand its unique network, and accelerate overall growth. The funding underscores Redi Health’s success...
Source: EMR and HIPAA - March 25, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Blue Heron Capital Gordon Crenshaw Health IT Funding Health IT Fundings Health IT Investment Jim Clair Luke Buchanan M25 Mutual Capital Partners North Coast Ventures Redi.Health Refinery Ventures Source Type: blogs

Will Americans Get PBM Reform in 2024? Maybe, But Many Things Need to Happen I Order to Get There. On the Upside: Insulin Has Opted Out of PBM Sales.
At the core of this post is a YouTube video which can be viewed in the middle of this blog post. The subject is about whether we ' ll get much-needed legislation passed into law to reform corrupt Pharmacy Benefit Managers (PBMs) which we know with absolute certainty were at fault for runaway insulin prices. At least that was true until March 2023, when the three largest insulin manufacturers, starting withLilly, followed byNovo Nordisk and shortly thereafter,Sanofi all announced major insulin list price reductions in the range of 70% to 78%. Think about that for a second: Imagine being able to instantly...
Source: Scott's Web Log - March 17, 2024 Category: Endocrinology Tags: 2024 Congress insulin prices PBM rebates reform Source Type: blogs

Will Americans Get PBM Reform in 2024? Maybe, But Many Things Need to Happen In Order to Get There. On the Upside: Insulin Has Opted Out of PBM Sales.
At the core of this post is a YouTube video which can be viewed in the middle of this blog post. The subject is about whether we ' ll get much-needed legislation passed into law to reform corrupt Pharmacy Benefit Managers (PBMs) which we know with absolute certainty were at fault for runaway insulin prices. At least that was true until March 2023, when the three largest insulin manufacturers, starting withLilly, followed byNovo Nordisk and shortly thereafter,Sanofi all announced major insulin list price reductions in the range of 70% to 78%. Think about that for a second: Imagine being able to instantly...
Source: Scott's Web Log - March 17, 2024 Category: Endocrinology Tags: 2024 Congress insulin prices PBM rebates reform Source Type: blogs

A Lengthy View of Everything that is Wrong with the Drug Development Industry
The primary problems with drug development are self-evident from the data. Firstly the process of drug development has become enormously more expensive over the past seventy years, a period in in which rapid technological progress has diminished the cost and effort required for any task in pharmacology and biotechnology by orders of magnitude. Secondly, the pace at which useful new medicines emerge in the clinic has diminished considerably, over the same period of technological progress in which the bounds of the possible have opened up enormously. The article I'll point out today is well worth reading, a lengthy treatment...
Source: Fight Aging! - March 12, 2024 Category: Research Authors: Reason Tags: Politics and Legislation Source Type: blogs

First Analysis Invests in Dina, Provider of Home-Centered Care Coordination Solutions
Digital Network Management and Coordination Solutions to Help Health Plans and Providers Improve Access to Home Centric Care First Analysis, a leading venture capital investor, has made a new investment in Dina, a provider of digital network management and coordination solutions for the Medicare Advantage and Managed Medicaid markets, with a focus on coordinating supplemental benefits and long-term services and supports (LTSS). First Analysis led the $7 million Series B round, with participation from existing investors Osage Venture Partners and First Trust Capital Partners, LLC. In December, SCAN Group, a mission-driven o...
Source: EMR and HIPAA - March 7, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Andrew Walsh Ashish V. Shah Corey Greendale dina First Analysis First Trust Capital Partners Health IT Funding Health IT Fundings Health IT Investment Osage Venture Partners SCAN Group Source Type: blogs

PhaseV Applies Machine Learning for Successful Clinical Trials
A clinical trial can cost hundreds of millions of dollars, and one of the major contributors to costs is recruiting and keeping human subjects. According to Dr. Raviv Pryluk, PhD, CEO and co-founder at PhaseV, machine learning can cut the number of subjects by 30 to 50 percent. In this video, he describes other ways that AI can make drug development more efficient. At the design stage, a drug company can run millions of simulations to determine where risks lie and what parameters are most promising. AI can help to choose not just the number of subjects, but their demographics, and what your goal (clinical endpoint) should ...
Source: EMR and HIPAA - March 1, 2024 Category: Information Technology Authors: Andy Oram Tags: AI/Machine Learning Clinical Health IT Company Healthcare IT Regulations Clinical Trials Clinical Trials AI Clinical Trials Machine Learning Healthcare IT Video Interviews Israeli Clinical Trials Israeli Health IT Pharma Pharma AI Source Type: blogs

Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
Using Novel Digital Twins of Clinical Trial Participants, Unlearn is Accelerating Clinical Research to Help Bring New Treatments to Patients Sooner Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, today announced a $50M Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital. This round of funding was secured to propel the company’s mission to advance AI to eliminate trial and error in medicine by investing in its people, data, engineering ca...
Source: EMR and HIPAA - February 29, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT 8VC Altimeter Capital Charles Fisher DCVC DCVC Bio Epic Ventures Health IT Funding Health IT Fundings Health IT Investment Insight Partners Mubadala Capital Necessary Venture Capital Pauline Yang Source Type: blogs

Generative AI in Your Desk Drawer: A Wealth of Uses
Previous articles in this series introduced the role of generative AI in the healthcare back office and examined its use in billing and revenue management. We’ll cover a lot of other uses in this article. Patient Contact and Care Management CEO Rahul Sharma of HSBlox says that the next version of its CureAlign platform will use generative AI to help improve the care management processes in its CareTracker module. Many patients need reminders, if not actually coaxing, to come in for appointments. The CureAlign platform personalizes outgoing communication based on past interactions with the patient. Sharma says that ...
Source: EMR and HIPAA - February 28, 2024 Category: Information Technology Authors: Andy Oram Tags: Administration AI/Machine Learning Ambulatory C-Suite Leadership Communication and Patient Experience Health IT Company Healthcare IT Hospital - Health System LTPAC Abhishek Sharma Accenture Administrative Burden AdvancedMD Amazo Source Type: blogs

Bonfire Analytics Raises Oversubscribed $2M Venture Round to Accelerate Digital Health, Medical Device, & Biotech Adoption Across Healthcare Providers
Bonfire Analytics Closes its First Venture Round to Scale its AI-Driven Sales Intelligence Platform for Healthtech Companies along with Building a Powerful Foundational Dataset Consisting of 300M+ Lives Worth of Medical & Prescription Claims, 2M+ Providers, and 1,000+ Population Health Variables Bonfire Analytics announces the closing of its first venture round with key institutional investors including Impulsum Ventures, Wedbush Ventures, and Plug & Play Ventures, along with participation from the Alchemist Accelerator and Venture For America. The round will fuel product and growth initiatives to further Bon...
Source: EMR and HIPAA - February 22, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Alchemist Accelerator Bonfire Analytics Ed Wilson Health IT Funding Health IT Fundings Health IT Investment Impulsum Ventures Jaya Pokuri Plug & Play Ventures Venture For America Vinay Nagaraj Wedb Source Type: blogs

Purdue Pharma, The Sackler Family, and The U.S. Opioid Epidemic
Lawrence J. Trautman (Prairie View A&M University), Larry D. Foster, II (Prairie View A&M University), Purdue Pharma, The Sackler Family, and The U.S. Opioid Epidemic (2023): During recent years, the continued outbreak of addiction in the United States has reached... (Source: HealthLawProf Blog)
Source: HealthLawProf Blog - February 13, 2024 Category: Medical Law Authors: Katharine Van Tassel Source Type: blogs

Which doctor treats “ Y-36 ” disease ?
If anyone thinks doctors are the only unique and gifted people, who can treat diseases and mitigate human sufferings , realize how incorrect their understanding of the world, humanity & reality. The ICD-11 , the latest code lists nearly 15000 diseases. Have a look at this much celebrated (respected ?) list put up by the world health organization There are so many entities in the list , that are man made and solution is right there in our minds. Zoom your eyes on the red rectangle. Impact of Y-36 Y-36 is a contagious endemic, transmitted by power, pride and foolishness . Y-36 along with violence i...
Source: Dr.S.Venkatesan MD - February 11, 2024 Category: Cardiology Authors: dr s venkatesan Tags: Uncategorized Source Type: blogs

Rune Labs Unveils $12 Million Strategic Round to Accelerate Adoption of Novel Parkinson ’s Technologies
Brings Total Raised to Over $42 Million Co-Founder of Nexus NeuroTech and Former Verily President of Medical Devices Jordi Parramon Joins as New Board Member Rune Labs, a precision neurology software and data company, today announced a strategic round of $12 million, increasing the total amount raised by the company to over $42 million. The round was led by new brain disorder fund, Nexus NeuroTech Ventures, with participation from existing investors, including Eclipse, DigiTx Partners, Moment Ventures, and TruVenturo GmbH. Jordi Parramon, PhD, CEO, General Partner, and Co-Founder of Nexus NeuroTech Ventures and former Pre...
Source: EMR and HIPAA - February 6, 2024 Category: Information Technology Authors: Healthcare IT News Tags: Health IT Company Healthcare IT Aspen Neuroscience Benjamin Stecher BlueRock Therapeutics Brian Pepin DigiTx Partners Eclipse Health IT Funding Health IT Fundings Health IT Investment Jordi Parramon Moment Ventures Nexus NeuroTec Source Type: blogs

Fight Aging! Newsletter, January 29th 2024
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter, please visit: https://www.fightaging.org/newsletter/ Longevity Industry Consulting Services Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 28, 2024 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

The Business Case for a Biosimilar Company to Bring a Copy of Levemir to Market
My readers may recall that in November 2023, I blogged that Novo Nordisk announced it plans to retire (stop making) its first " Lantus killer " known as Levemir (insulin detemir injection) in the U.S. in 2024 (catch my post at https://blog.sstrumello.com/2023/11/novo-nordisk-to-discontinue-levemir-in.html for more). At the time I learned of the announcement, I was on vacation in Amsterdam, so I just made a note of the development and blogged about it a few weeks later upon my return.Like other patients my age, I have endured the company ' s previous insulin " retirements " . Novo Nordisk ' s time-frame for withdr...
Source: Scott's Web Log - January 25, 2024 Category: Endocrinology Tags: 2024 Biosimilar Levemir Novo Nordisk PBM Source Type: blogs